The luteinizing hormone-releasing hormone (LHRH) analog leuprolide provides safe, reversible, and effective means for testosterone suppression in prostate cancer.1 By virtue of its mechanism of action, however, leuprolide initially raises testosterone levels before achieving castration, potentially leading to symptomatic flare in advanced disease.2 The LHRH antagonist degarelix was developed in part to avoid this, achieving faster, safer, and more consistent testosterone suppression.3-8. Here, GNRH1 is linked to Familial prostate cancer.